Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG NFLX BIIB AMZN IBB TSLA WYNN ALXN SLXP AMGN GMCR CNQR COST Z VRTX GILD AAPL MDVN SNDK
Nyse: ACT V LNKD IVV PXD IBM GS LMT AGN SPG FDX WHR TWC MMM CMI HUM APD BA GD XEC
New Highs: LMT FDX NSC GPRO NKE INTU DRC CCI FB DUK ETP HRL MO KO NI MAS

The Hot Industries

Diversified Utilities 2
Oil & Gas Pipelines 1
Meat Products 1

The Hot Sectors

Consumer Goods 4
Industrial Goods 3
Technology 3

TNX Stock Chart

TNX

favicon

Tonix Pharmaceuticals Holding (TNXP) Sank To A 10-Month Low After Study Failed

30 Sep 2014, 5:49 amTonix Pharmaceuticals Holding (TNXP) announced Monday morning that its Phase 2b BESTFIT study of TNX-102 SL as a chronic bedtime treatment for fibromyalgia, did not achieve statistical significance in the primary efficacy endpoint of change in average daily pain score at week 12.
favicon

TNXP: Tonix reports results from the Phase 2b/3 BESTFIT trial

29 Sep 2014, 5:00 pmOn September 29, 2014, Tonix Pharmaceuticals (TNXP) announced top line results for the Phase 2b/3 BESTFIT trial. The study did not achieve statistical significance in the primary efficacy endpoint of change in average daily pain score at week 12 (p=0.086 by mixed-effect model repeated measure analysis, p=0.172 by jump-to-control, multiple imputation analysis). Below we will briefly review the ...
favicon

Sector Update: Health Care Narrowly Lower at Close; Alcobra Continues Skid Prior to Reporting ADHD Drug Results

29 Sep 2014, 2:47 pmSector Update: Health Care Narrowly Lower at Close; Alcobra Continues Skid Prior to Reporting ADHD Drug Results
favicon

Sector Update: Health Care Stocks Slightly Lower; AMAG Pharma Springs Higher on $675 Mln Deal for Lumara Health

29 Sep 2014, 12:42 pmSector Update: Health Care Stocks Slightly Lower; AMAG Pharma Springs Higher on $675 Mln Deal for Lumara Health
favicon

Sector Update: Health Care

29 Sep 2014, 12:40 pmSector Update: Health Care
favicon

Tonix Pharma's pain drug fails mid-stage study

29 Sep 2014, 8:45 amTonix Pharmaceuticals Holding Corp said its lead drug for pain management failed the main goal of a mid-stage study, sending its down by more than half in early trading. The drug, TNX-102, is being tested to treat fibromyalgia, a chronic syndrome characterized by widespread pain and lack of sleep. The treatment failed the main goal of reducing pain experienced by patients by the 12th week of the ...
favicon

Tonix Pharmaceuticals Holding (TNXP) Is Sinking After Phase 2 Study Failed

29 Sep 2014, 8:12 amTonix Pharmaceuticals Holding (TNXP) announced Monday morning that its Phase 2b BESTFIT study of TNX-102 SL as a chronic bedtime treatment for fibromyalgia, did not achieve statistical significance in the primary efficacy endpoint of change in average daily pain score at week 12.
favicon

Tonix Pharma Reports Top Line Results From Phase 2b BESTFIT Trial Of TNX-102 SL

29 Sep 2014, 4:20 amTonix Pharma Reports Top Line Results From Phase 2b BESTFIT Trial Of TNX-102 SL
favicon

Tanzanian Royalty Announces Grade Control Drilling Results for Mining Production from Buckreef South Pit

8 Sep 2014, 12:55 pmVANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 8, 2014) - Tanzanian Royalty Exploration Corporation (TSX:TNX)(NYSE MKT:TRX) is pleased to report the results of 250 grade control drill holes completed on the Buckreef South Pit at its Buckreef Re-development Gold Project in Tanzania. In addition to the previously announced exploration and development drilling results on the grade control ...
favicon

Tanzanian Royalty Exploration Corporation Completes Heap Leach Pad Construction

2 Sep 2014, 1:55 pmVANCOUVER, BRITISH COLUMBIA--(Marketwired - Sept. 2, 2014) - Tanzanian Royalty Exploration Corporation (TSX:TNX)(NYSE MKT:TRX) is pleased to announce the completion of its heap leach pad construction at its Buckreef Re-development Gold Project, located in the Lake Victoria Goldfields of Tanzania. Construction began in April 2014 and was overseen by civil contractor Yale-Constech Company Limited.